| Literature DB >> 35628223 |
Abstract
Mast cells (MCs) and macrophages (Mϕs) are innate immune cells that differentiate from early common myeloid precursors and reside in all body tissues. MCs have a unique capacity to neutralize/degrade toxic proteins, and they are hypothesized as being able to adopt two alternative polarization profiles, similar to Mϕs, with distinct or even opposite roles. Mϕs are very plastic phagocytic cells that are devoted to the elimination of senescent/anomalous endogenous entities (to maintain tissue homeostasis), and to the recognition and elimination of exogenous threats. They can adopt several functional phenotypes in response to microenvironmental cues, whose extreme profiles are the inflammatory/killing phenotype (M1) and the anti-inflammatory/healing phenotype (M2). The concomitant and abundant presence of these two cell types and the partial overlap of their defensive and homeostatic functions leads to the hypothesis that their crosstalk is necessary for the optimal coordination of their functions, both under physiological and pathological conditions. This review will examine the relationship between MCs and Mϕs in some situations of homeostatic regulation (menstrual cycle, embryo implantation), and in some inflammatory conditions in the same organs (endometriosis, preeclampsia), in order to appreciate the importance of their cross-regulation.Entities:
Keywords: cytokines; inflammation; innate immunity; macrophages; mast cells; menstruation; peritoneum; polarization; pregnancy; uterus
Mesh:
Substances:
Year: 2022 PMID: 35628223 PMCID: PMC9142086 DOI: 10.3390/ijms23105414
Source DB: PubMed Journal: Int J Mol Sci ISSN: 1422-0067 Impact factor: 6.208
Figure 1Schematic view of fetal hematopoiesis. Transient (definitive) and definitive waves, as well as local organ distribution of multipotent progenitors, committed-progenitors, and mature cells are shown. These sequential waves partially overlap in time and space. This figure was generated with BioRender and PowerPoint.
Figure 2Representative picture of the main characteristics of MCs and Mϕs listed in this review. The mediators, cytokines, and enzymes produced following the activation of the receptors present on the cells are shown in the figure and are described in the text of the review. This figure was generated with Adobe Illustrator and PowerPoint.
Schematic description of the MC and Mɸ receptors, ligands, and functions mentioned in this review.
| Receptor | Ligand | Expression | Function |
|---|---|---|---|
| TLR2 | Bacterial, viral, fungal and parasites lipids, proteins, polysaccharides | MC and M1 | Pro-inflammatory cytokines production, degranulation [ |
| TLR4 | Bacterial and viral proteins | MC and M1 | Pro-inflammatory cytokines production, degranulation [ |
| FcεRI | Allergens | MC | Allergic reaction [ |
| CD14 | Endotoxin receptor | Mɸ | Pro-inflammatory cytokine production [ |
| F4/80 | Marker mouse | Mɸ | Differentiation, induction of CD8+ T regulatory cells [ |
| c-KIT | SCF | MCs | Migration, differentiation, and survival [ |
| NK-R1 | Substance P | Mɸ | Pro-inflammatory cytokines, NO, ROS, production. Induction of COX-2 activity [ |
| MRGPR | Substance P | MC | Pro-inflammatory cytokine production, histamine and protease release [ |
Figure 3Timeline of hormone production and different phases during the menstrual cycle in humans. Figure generated using PowerPoint.
Figure 4Schematic picture of the cycling non-pregnant human uterus with endometrium and myometrium tissue, and Mϕs, MCT, and MCTC localization under physiological conditions. Abbreviations: Mast cells tryptase (MCT), Mast cells tryptase, chymase (MCTC). This figure was generated using BioRender and modified in PowerPoint.
Cytokines and mediators produced by uterine mast cells and macrophages during the different phases of the menstrual cycle under physiological conditions. Abbreviations: uMɸs (uterine Mɸs); uMCs (uterine MCs); mMCs (myometrial MCs) [64,68,69,70,71,74,75,76,77,78].
| Phase | Cell | Molecules/Status | Ref. |
|---|---|---|---|
| Proliferative | uMϕ | TNF-α; IL-1β; IL-10; IL-1RA; VEGF; FGF2; PDFG; phagocytosis; | [ |
| Proliferative | uMC | Steady state | [ |
| Secretory | uMϕ | IL-11; activin; CD163 (70%) | [ |
| Mid-late secretory | uMC | Tryptase; chymase; TNF-α; histamine; heparin | [ |
| Menstrual repair | uMϕ | TNF-α; MMP-9; MMP-12; MMP-14 | [ |
| Menstrual | mMC | Tryptase; chymase | [ |
Figure 5Timeline of pregnancy steps and the pro-inflammatory and anti-inflammatory physiological conditions of the microenvironment generated by the activity of immune cells. Figure generated with PowerPoint.
MCs and Mϕs phenotypes, functions, and biomolecules produced during different stages of early pregnancy. Abbreviations: MCC—mast cell chymase, MCTC—mast cell tryptase-chymase [36,63,69,72,73,87,97,99,102,107,108,109,110,111,112,113,114,115,116,117].
| Time | Phenotype | Function | Production | References |
|---|---|---|---|---|
| Pre-implantation/human, mouse | M1 | ECM digestion, engulf apoptotic cells | MMP-7; MMP-9; Gelatinase | [ |
| Pre-implantation | M2 | Remodeling | VEGF, IGF, Fn1, MMPs | [ |
| Pre-implantation/human, murine | MCs | Remodeling | Histamine, chymase, | [ |
| Implantation | M1 | Favor implantation, vascular remodeling, angiogenesis | TNF-α, VEGF, PDGF, FGF, MMP3, MMP9; IL-1β | [ |
| Implantation/human, mouse | MCC | Vascular remodeling, fetal growth, migration and proliferation of extravillous | MMPs, VEGF, FGF, histamine, tryptase, leptin, cytokines | [ |
| Post-implantation | M2 | Maternal–fetal tolerance | IL-10, IL-1β, Il-6, TNF-α; PGE2 | [ |
| Post-implantation | MCTC | Maternal– fetal tolerance | TGF-β IL-10, LIF | [ |
| Early pregnancy | MCTC | Placenta formation | Histamine, Gal-1 | [ |
Placental MCs and Mϕs: Appearance, function, and biomolecules produced during different stages of pregnancy. Abbreviations: MCC—mast cell chymase, MCTC—mast cell tryptase-chymase [36,37,141,142].
| Time | Phenotype | Function | Production | References |
|---|---|---|---|---|
| 1st–2nd trimester | M1 | Maternal–fetal tolerance | TNF-α, IL-6, IL-12, IL-23, IFN-γ, IL-18 | [ |
| 1st–2nd trimester | M2 | Maternal–fetal tolerance | IL-4, IL-10, VEGF, IGF, FN | [ |
| 2nd–3rd trimester | M2 | Maternal–fetal tolerance | VEGF, IL-6, IL-10 | [ |
| End of pregnancy | M1 | Favor labor, remove apoptotic cells | IL-6, IL-10, IL-1, TNF-α, IFN-γ | [ |
| End of pregnancy | MC | Favor labor | Histamine | [ |